| Home / Features / Health / Lung Cancer | Print / Comments |
|
|
Imogen Thomas
Posted a snap of herself
Francois Hollande
New French President
Manchester City
Wins Premier League 2011-12
Beyonce Knowles
Voted among Most Powerful Moms
Joey Barton
sent off in the final Premier League match
Usain Bolt
Dumps girlfriend to concentrate on Olympics
Facebook
IPO this month
A Raja
granted bail in 2G scam
Rekha
Takes oath as Rajya Sabha member
Satyameva Jayate
Gets high TRP ratings
Lung cancer is the second most common cause of death among women. A recent trend show that Lung cancer becomes biggest killer of Australian women.
A diverse diet of fruits and vegetables may decrease the risk of lung cancer - especially if you smoke.
Decision Resources, a research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013.
Actress Patricia Neal died from lung cancer in August 2010, at the age of 84.
Rosetta Genomics Achieves Major Commercial Milestone by Obtaining Medicare Coverage of miRview mets2 Assay
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview® mets² assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries
Helix BioPharma Corp. Commences Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that clinical site initiation and patient recruitment activities in its Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 have commenced in Poland.
MolMed Board of Directors Approves the Interim Financial Report at 31 March 2012
The Board of Directors of MolMed S.p.A. (MILAN: MLM), chaired by Professor Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2012.
Researchers Present Data Highlighting Potential of Peregrine's PS-Targeting Antibodies to Treat Ocular Herpes Infections and Macular Degeneration
Peregrine Pharmaceuticals, Inc
Agennix AG Reports Financial Results for First Quarter of 2012
Agennix AG (FRANKFURT: AGX) (XETRA: AGX), a biopharmaceutical company focused on developing novel therapies that have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need, today announced financial results for the first quarter and three months ended March 31, 2012.
Agennix AG to Present at BioEquity Europe 2012 on May 15
Agennix AG (FRANKFURT: AGX) today announced that the Company will give a presentation at the 13th Annual BioEquity Europe 2012 Conference on Tuesday, May 15, 2012 at 14:00 CET, Level 1, Room Gold 2, at the Marriott Hotel in Frankfurt/Main, Germany. The Company's presentation will be made available on the Agennix website following the event.
Agennix AG Schedules Conference Call on May 9 to Discuss First Quarter 2012 Financial Results
Agennix AG (FRANKFURT: AGX) today announced that the Company will host a conference call to discuss first quarter 2012 financial results and provide a business update on May 9, 2012.
Peregrine's Novel PS-Targeting Technology Platform to Be Highlighted at The New York Academy of Sciences Symposium on May 1, 2012
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that its phosphatidylserine (PS)-targeting technology platform and its lead drug candidate, bavituximab, will be highlighted at a symposium hosted by The New York Academy of Sciences
Rosetta Genomics Receives Key U.S. Patent Allowance
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced receipt of a patent allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Application 12/800,556 titled, "MICRORNAS AND USES THEREOF
Rosetta Genomics Receives Key European Patent in Oncology
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a grant from the European Patent Office for a patent claiming the use of miR-34a for the preparation of pharmaceuticals for treating p53-negative cancers
Gemma Spofforth reveals suicidal despair after string of personal tragedies
British swimmer Gemma Spofforth, who has been tipped for gold medal glory at the London Olympics, has had to pull herself back from the brink to compete in the 100 metres backstroke at this summer's games.
Persistent cough 'could signal lung cancer'
A new government advertising drive has warned the public to be vigilant about persistent coughs as they could be a sign of lung cancer.
Potential 'dark side' of diets high in beta-carotene revealed
Consumption of excessive amounts of beta-carotene, a naturally occurring pigment that gives colour to foods such as carrots, sweet potatoes and certain greens, may be hazardous to health, suggests a new study.
'Brake gene' switched off in pancreatic cancer
Researchers have explored a new class of drugs, which may bring treatment of aggressive pancreatic tumours closer to reality.
Quality of life 'as important as quantity of life' for cancer survivors
Researchers have stressed on the importance of gathering data about cancer patients' quality of life during both treatment and survivorship.
Shaft guitarist Charles 'Skip' Pitts passes away at 65
Revered soul guitarist, Charles 'Skip' Pitts, died on Tuesday in Memphis after a long struggle with cancer. He was 65.
Men `to outlive women` as better habits boost health
Men ditching unhealthy lifestyles may soon be able to live longer than women or have the same life expectancy as females for the first time since records began, a new study has revealed.
Indonesian health minister resigns
Indonesian President Susilo Bambang Yudhoyono said on Thursday that he agreed on the proposal of Health Minister Endang Rahayu Sedyaningsih to resign as the minister could not perform duty properly due to cancer treatment she has been undergoing, according to sources.
Media Alert: Pivotal Phase III results for afatinib* in lung cancer to be presented at ASCO 2012
FOR NON-US MEDIA ONLY
Beach Boys reuniting to mark golden anniversary in 2012
The surviving members of band 'The Beach Boys' are planning to reunite in 2012 to celebrate their golden anniversary year, commemorating their first important record deal with the Capitol label.
How shed retreats can help men live longer
Retreating at a humble garden shed may help men live longer, health experts say.
Peregrine Provides Update on HCV Clinical Program
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV)
Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer
STOCKHOLM, SWEDEN - December 28, 2011. Axelar AB, a Karolinska Development AB portfolio company, today announces that the first patient has been dosed in a randomized Phase II study on non-small cell lung cancer (NSCLC) patients of its drug candidate AXL1717
Verisante Starts FDA Approval Process and Provides Operational Update
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF)(PINKSHEETS: VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura
Rosetta Genomics Sells Ownership in Rosetta Green
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held. Prior to the transaction, Rosetta Genomics owned approximately 50
Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.
BioServe Expands Relationship With Fox Chase Cancer Center
BioServe today announced an expanded relationship with Fox Chase Cancer Center, a foundation member of the BioServe Network of leading sample biorepositories. In this expanded relationship, BioServe will be working with Fox Chase to provide clients with next generation sequencing capabilities
Rosetta Genomics Announces New York State Approval for miRview mets²
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced that the New York State Department of Health has approved miRview® mets² for testing on patient samples from the state. New York is the only U.S. state that requires an independent regulatory review process for laboratory developed tests
Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients
Frost & Sullivan Commends Biodesix for Raising the Bar in Personalized Medicine Diagnostics With the VeriStrat(R) Test
Based on its recent analysis of the cancer diagnostics market, Frost & Sullivan recognizes Biodesix with the 2011 North America Frost & Sullivan Award for Product Differentiation Excellence. Biodesix's significant investment in validation, clinical research and basic R&D has made it a leading diagnostic service provider in an industry that often lacks clinically validated biomarkers
Study Showing Potential for microRNAs as Biomarkers for Heart Failure Prognosis Published in European Journal of Heart Failure
Rosetta Genomics, Ltd
Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 23
Soon, biosensors to detect lung cancer from exhaled breath
Scientists are developing biosensors capable of detecting the presence of tumour markers of lung cancer in exhaled breath.
Soybean compounds enhances effects of cancer radiotherapy
Compounds found in soybean compounds make radiation therapy to treat lung cancer tumours more effective, a new study has revealed.
Radiation therapy to become more effective and safer
Radiation therapy may soon have fewer side effects and doubled efficiency, a new study has revealed.
Now, breath test can detect, characterize lung cancer
A new breath test will now help in identifying and differentiating between the types of lung cancer in humans with high accuracy, a new study has suggested.
Aspirin significantly cuts cancer risk
A daily dose of aspirin can sharply reduce the risk of death from a wide range of cancers, a new study has suggested.
Tiny genetic variation can predict outcome of ovarian cancer treatment
A tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer, a new study has shown.